Why the study?
Do traditional and innovative pharmacological therapies (digitoxin, beta-blockers, vericiguat, dapagliflozin) improve cardiovascular outcomes in patients with HFrEF and post-MI?
RCT (n=2,401)
Double-blind
1:1
Yes
Do traditional and innovative pharmacological therapies (digitoxin, beta-blockers, vericiguat, dapagliflozin) improve cardiovascular outcomes in patients with HFrEF and post-MI?
Effect estimate: HR 0.86 (95% CI 0.68-1.08)
Absolute Event Rate: 10.9% vs 12.7%
p-value: p=0.20
Recent trials highlight the need for tailored therapy in HF and post-MI, showing modest benefits for digitoxin and vericiguat in HFrEF, lack of universal benefit for beta-blockers in preserved EF post-MI, and safety of early SGLT2 initiation.
Supports early SGLT2 inhibitor use in hospitalized HF; leaves open optimal timing and subgroups pending dedicated trials.
NEW late breaking trials in heart failure (HF) continue to refine therapy in patients with heart failure with reduced ejection fraction (HFrEF) and post-myocardial infarction (MI). DIGIT-HF,1 BETAMI-DANBLOCK,2 REBOOT-CNIC,3 VICTOR,4 and DAPA ACT HF-TIMI 685 are some studies presenting novel evidence on pharmacological therapy optimisation, including digitoxin, β-blockers, vericiguat, and sodium glucose co-transporter-2 (SGLT2) inhibitors. These studies highlight the strategic use of traditional and innovative therapies, taking patient-specific traits, comorbidities, and time of intervention into account. Interpretation of these studies proves critical for optimisation of benefits and guiding patient-specific HF management.
No takes yet. Share an insight, caveat, or question.
Han Naung Tun (2025) conducted an RCT in hospitalized heart failure (n=2,401). dapagliflozin vs. placebo was evaluated on composite of cardiovascular death or worsening heart failure (HR 0.86, 95% CI 0.68-1.08, p=0.20).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: